Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

Gregory Takacs, BS, Yujia Zhou, BS,BA, David J. King, BS, Amy Meacham, MS, Loguinov Alex, PhD, Abderrahmane Tagmount, PhD, Amin Sobh, PhD, Max Russo, BS, Chris D Vulpe, MD PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 1452.

https://doi.org/10.1182/blood-2019-128180

Published: 2019

Journal Articles

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Madeleine Turcotte, MS, Raphael Charles Bosse, BS, MD PhD, Kimberly E. Hawkins, PhD BS, Amy Meacham, MS, Vindhya Vijay, MS, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Ansu Kumar, MS, Shwetha K, BE, Anisha Kamath, BT, Anjana T. Nair, MS, Karthik S. Raju, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD

Blood (2017) 130 (Supplement 1): 1448.

https://doi.org/10.1182/blood.V130.Suppl_1.1448.1448

Published: 2017

Journal Articles

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Raphael C Bosse, BS, Briana Wasserstrom, Elizabeth Wise, BS, Amy Meacham, MS, Christopher R. Cogle, MD

Blood (2014) 124 (21): 2315.

https://doi.org/10.1182/blood.V124.21.2315.2315

Published: 2014

Journal Articles

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Daniel Turner, BS, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Raphael C Bosse, BS, Dai Chaplin, PhD, Jack W. Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, Maxim Norkin, MD, PhD, John R Wingard, MD, Christopher R Cogle, MD

Blood (2013) 122 (21): 1463.

https://doi.org/10.1182/blood.V122.21.1463.1463

Published: 2013

Journal Articles

Bone Marrow Endothelial Cells Protect Acute Myeloid Leukemia From Chemotherapy By Direct Contact: The BCAM/Laminin/VLA5 Axis As a Potential Therapeutic Target

Leylah Drusbosky, BS, Amy Meacham, MS, Elizabeth Wise, BS, Edward W Scott, PhD, Christopher R Cogle, MD

Blood (2013) 122 (21): 2546.

https://doi.org/10.1182/blood.V122.21.2546.2546

Published: 2013

Journal Articles

Peripheral Blood CD34 + Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.

Maxim Norkin, MD, PhD, Amy Meacham, MS, Mai H Ta, MT, Neil Benson, MS, Steven Goldstein, MD, Emma Rosenau, MPH, Jack W. Hsu, MD, Christopher R. Cogle, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2012) 120 (21): 3074.

https://doi.org/10.1182/blood.V120.21.3074.3074

Published: 2012

Journal Articles

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton.

Raphael C Bosse, BS, Sunil Rohatgi, BS, Amy Meacham, MS, Elizabeth Wise, BS, Edward W Scott, PhD, Christopher R Cogle, MD

Blood (2012) 120 (21): 2183.

https://doi.org/10.1182/blood.V120.21.2183.2183

Published: 2012

Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD

Blood (2012) 120 (21): 4335.

https://doi.org/10.1182/blood.V120.21.4335.4335

Published: 2012

Journal Articles

Acute Myeloid Leukemia Cells Generate Leukemic Endothelial Cells with Leukemogenic Potential: Blood Vessels As Sanctuaries for Leukemia Relapse

Christopher R Cogle, M.D., Gerard J Madlambayan, PhD, Devorah C Goldman, Ph.D., Azzah Al Masri, Ronald P. Leon, Ph.D., Jennifer Dunlap, Tibor Kovacsovics, MD, Qiuying Liu, Amy Meacham, MS, Edward W Scott, Ph.D., William H Fleming, MD, PhD

Blood (2011) 118 (21): 241.

https://doi.org/10.1182/blood.V118.21.241.241

Published: 2011

Journal Articles

AML Depends on VEGFR1 and Not VEGFR2 for Proliferation and Protection From Chemotherapy,

Swarna Bais, Ph.D., Elizabeth Wise, B.S., Eric M. Harris, DO, Amy Meacham, MS, Christopher R Cogle, M.D.

Blood (2011) 118 (21): 3598.

https://doi.org/10.1182/blood.V118.21.3598.3598

Published: 2011

Journal Articles

Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.

Eric Gars, Christie S McGee, Raphael C Bosse, Elizabeth Wise, Amy Meacham, MS, Christopher R. Cogle, MD

Blood (2010) 116 (21): 1057.

https://doi.org/10.1182/blood.V116.21.1057.1057

Published: 2010

Journal Articles

AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.

Gerard J Madlambayan, Ph.D., Amy Meacham, M.S., Koji Hosaka, Ph.D., Saad Mir, Marda Jorgensen, Edward W Scott, Ph.D., Dietmar W. Siemann, Ph.D., Christopher R. Cogle, M.D.

Blood (2009) 114 (22): 1031.

https://doi.org/10.1182/blood.V114.22.1031.1031

Published: 2009

NARROW

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Bone Marrow Endothelial Cells Protect Acute Myeloid Leukemia From Chemotherapy By Direct Contact: The BCAM/Laminin/VLA5 Axis As a Potential Therapeutic Target

Peripheral Blood CD34 + Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton.

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia Cells Generate Leukemic Endothelial Cells with Leukemogenic Potential: Blood Vessels As Sanctuaries for Leukemia Relapse

AML Depends on VEGFR1 and Not VEGFR2 for Proliferation and Protection From Chemotherapy,

Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.

AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only